{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:22:09Z","timestamp":1759936929267},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00059-017-4648-0","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T06:25:59Z","timestamp":1510899959000},"page":"2-10","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anticoagulation in atrial fibrillation"],"prefix":"10.1007","volume":"43","author":[{"given":"J. W.","family":"Erath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"4648_CR1","doi-asserted-by":"crossref","first-page":"e001684","DOI":"10.1161\/JAHA.114.001684","volume":"4","author":"MC Bennell","year":"2015","unstructured":"Bennell MC, Qiu F, Micieli A et al (2015) Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a\u00a0population-based study. J\u00a0Am Heart Assoc 4:e1684","journal-title":"J Am Heart Assoc"},{"key":"4648_CR2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K et\u00a0al (2014) Worldwide epidemiology of atrial fibrillation: a\u00a0global burden of disease 2010 study. Circulation 129:837\u2013847","journal-title":"Circulation"},{"key":"4648_CR3","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:2N\u20139N","journal-title":"Am J Cardiol"},{"key":"4648_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.158.3.229","volume":"158","author":"PA Wolf","year":"1998","unstructured":"Wolf PA, Mitchell JB, Baker CS et\u00a0al (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229\u2013234","journal-title":"Arch Intern Med"},{"key":"4648_CR5","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/STROKEAHA.116.012865","volume":"47","author":"N Henninger","year":"2016","unstructured":"Henninger N, Goddeau RP Jr, Karmarkar A et al (2016) Atrial fibrillation is associated with a\u00a0worse 90-day outcome than other cardioembolic stroke subtypes. Stroke 47:1486\u20131492","journal-title":"Stroke"},{"key":"4648_CR6","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","volume":"110","author":"BF Gage van","year":"2004","unstructured":"van Gage BF, Walraven C, Pearce L et\u00a0al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287\u20132292","journal-title":"Circulation"},{"key":"4648_CR7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857","journal-title":"Ann Intern Med"},{"key":"4648_CR8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner CD et\u00a0al (2011) Apixaban in patients with atrial fibrillation. N\u00a0Engl J Med 364:806\u2013817","journal-title":"N Engl J Med"},{"key":"4648_CR9","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et\u00a0al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart\u00a0J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"4648_CR10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et\u00a0al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"4648_CR11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"ROCKET AF Investigators, Patel MR, Mahaffey KW, Garg J et\u00a0al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N\u00a0Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"4648_CR12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et\u00a0al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"4648_CR13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Once-daily edoxaban versus warfarin in patients with atrial fi brillation. N\u00a0Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"4648_CR14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a\u00a0meta-analysis of randomised trials. Lancet 383:955\u2013962","journal-title":"Lancet"},{"key":"4648_CR15","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cjca.2016.07.591","volume":"32","author":"L Macle","year":"2016","unstructured":"Macle L, Cairns J, Leblanc K et\u00a0al (2016) 2016 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 32:1170\u20131185","journal-title":"Can J Cardiol"},{"key":"4648_CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","volume":"13","author":"A Gorst-Rasmussen","year":"2015","unstructured":"Gorst-Rasmussen A, Skj\u00f8th F, Larsen TB et al (2015) Dabigatran adherence in atrial fibrillation patients during the first year diagnosis: a\u00a0nationwide cohort study. J\u00a0Thromb Haemost 13:495\u2013504","journal-title":"J Thromb Haemost"},{"key":"4648_CR17","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","volume":"2","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Holmes DN, Piccini JP et\u00a0al (2013) Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from outcomes registry for better informed treatment of atrial fibrillation. J\u00a0Am Heart Assoc 2:e535. \n                        https:\/\/doi.org\/10.1161\/JAHA.113.000535","journal-title":"J Am Heart Assoc"},{"key":"4648_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR et\u00a0al (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J\u00a0Am Heart Assoc. \n                        https:\/\/doi.org\/10.1161\/JAHA.116.003725","journal-title":"J Am Heart Assoc"},{"key":"4648_CR19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","volume":"116","author":"GY Lip","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S et al (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity-score matched analysis. Thromb Haemost 116:975\u2013986","journal-title":"Thromb Haemost"},{"key":"4648_CR20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/03007995.2017.1347090","volume":"33","author":"S Deitelzweig","year":"2017","unstructured":"Deitelzweig S, Farmer C, Luo X et al (2017) Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a\u00a0systematic review of real-world observational studies. Curr Med Res Opin 33:1583\u20131594","journal-title":"Curr Med Res Opin"},{"key":"4648_CR21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","volume":"106","author":"SH Hohnloser","year":"2017","unstructured":"Hohnloser SH, Basic E, N\u00e4bauer M (2017) Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a\u00a0post-marketing surveillance study. Clin Res Cardiol 106:618\u2013662","journal-title":"Clin Res Cardiol"},{"key":"4648_CR22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.amjcard.2016.01.024","volume":"117","author":"T Gr\u00f6nberg","year":"2016","unstructured":"Gr\u00f6nberg T, Hartikainen JE, Nuotio I et\u00a0al (2016) Anticoagulation, CHA2DS2VASc Score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV Study). Am J Cardiol 117:1294\u20131298","journal-title":"Am J Cardiol"},{"key":"4648_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","volume":"123","author":"R Nagarakanti","year":"2011","unstructured":"Nagarakanti R, Ezekowitz MD, Oldgren J et\u00a0al (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123:131\u2013136","journal-title":"Circulation"},{"key":"4648_CR24","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","volume":"61","author":"JP Piccini","year":"2013","unstructured":"Piccini JP, Stevens SR, Lokhnygina Y et\u00a0al (2013) Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J\u00a0Am Coll Cardiol 61:1998\u20132006","journal-title":"J Am Coll Cardiol"},{"key":"4648_CR25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","volume":"63","author":"G Flaker","year":"2014","unstructured":"Flaker G, Lopes RD, Al-Khatib SM et al (2014) Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J\u00a0Am Coll Cardiol 63:1082\u20131087","journal-title":"J Am Coll Cardiol"},{"key":"4648_CR26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/clc.22537","volume":"39","author":"A Plitt","year":"2016","unstructured":"Plitt A, Ezekowitz MD, De Caterina R et al (2016) Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 39:345\u2013346","journal-title":"Clin Cardiol"},{"key":"4648_CR27","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","volume":"35","author":"R Cappato","year":"2014","unstructured":"Cappato R, Ezekowitz MD, Klein AL et\u00a0al (2014) Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart\u00a0J 35:3346\u20133355","journal-title":"Eur Heart J"},{"key":"4648_CR28","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD et al (2016) Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a\u00a0randomised, open-label, phase 3b trial. Lancet 388:1995\u20132003","journal-title":"Lancet"},{"key":"4648_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2016.06.008","volume":"179","author":"MD Ezekowitz","year":"2016","unstructured":"Ezekowitz MD, Pollack CV, Sanders P et\u00a0al (2016) Apixaban compared with parenteral heparin and\/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial. Am Heart\u00a0J 179:59\u201368","journal-title":"Am Heart J"},{"key":"4648_CR30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/europace\/eus027","volume":"14","author":"H Calkins","year":"2012","unstructured":"Calkins H, Kuck KH, Cappato R et al (2012) 2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528\u2013606","journal-title":"Europace"},{"key":"4648_CR31","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"L Biase Di","year":"2014","unstructured":"Di Biase L, Burkhardt JD, Santangeli P et\u00a0al (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 129:2638\u20132644","journal-title":"Circulation"},{"key":"4648_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00059-015-4383-3","volume":"41","author":"SH Hohnloser","year":"2016","unstructured":"Hohnloser SH (2016) Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation. Herz 41:37\u201347","journal-title":"Herz"},{"key":"4648_CR33","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","volume":"36","author":"R Cappato","year":"2015","unstructured":"Cappato R, Marchlinski FE, Hohnloser SH et al (2015) Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart\u00a0J 36:1805\u20131811","journal-title":"Eur Heart J"},{"key":"4648_CR34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP et\u00a0al (2017) Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N\u00a0Engl J Med 376:1627\u20131636","journal-title":"N Engl J Med"},{"key":"4648_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.09.011","author":"R Cardoso","year":"2017","unstructured":"Cardoso R, Knijnik L, Bhonsale A et al (2017) An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted Anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. \n                        https:\/\/doi.org\/10.1016\/j.hrthm.2017.09.011","journal-title":"Heart Rhythm"},{"key":"4648_CR36","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Windecker S, Huber K et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a\u00a0joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart\u00a0J 35:3155\u20133179","journal-title":"Eur Heart J"},{"key":"4648_CR37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJM Dewilde","year":"2013","unstructured":"Dewilde WJM, Oirbans T, Verheugt FWA et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107\u20131115","journal-title":"Lancet"},{"key":"4648_CR38","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","volume":"8","author":"LR Jackson II","year":"2015","unstructured":"Jackson LR II, Ju C, Zettler M et al (2015) Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv 8:1880\u20131889","journal-title":"JACC Cardiovasc Interv"},{"key":"4648_CR39","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et\u00a0al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N\u00a0Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"4648_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et\u00a0al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N\u00a0Engl J Med. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1708454","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4648-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T11:17:16Z","timestamp":1518002236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4648-0"}},"subtitle":["Current evidence and guideline recommendations"],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4648-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]}}}